CoChat

Activity of a first-in-class oral HIF2-alpha inhibitor, PT2385, in patients with first recurrence of glioblastoma

Open access
Strowd, Roy, Ellingson, Benjamin, Raymond, Catalina, Yao, Jingwen, Wen, Patrick Y., Ahluwalia, Manmeet, Piotrowski, Anna, Desai, Arati, Clarke, Jennifer L., Lieberman, Frank S., Desideri, Serena, Nabors, L. Burt, Ye, Xiaobu, Grossman, Stuart · 2023 · Journal of Neuro-Oncology
Cited by 36

The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.

Abstract

Hypoxia inducible factor 2-alpha (HIF2α) mediates cellular responses to hypoxia and is over-expressed in glioblastoma (GBM). PT2385 is an oral HIF2α inhibitor with in vivo activity against GBM. A two-stage single-arm open-label phase II study of adults with GBM at first recurrence following chemoradiation with measurable disease was conducted through the Adult Brain Tumor Consortium. PT2385 was administered at the phase II dose (800 mg b.i.d.). The primary outcome was objective radiographic response (ORR = complete response + partial response, CR + PR); secondary outcomes were safety, overall survival (OS), and progression free survival (PFS). Exploratory objectives included pharmacokinetics (day 15 Cmin), pharmacodynamics (erythropoietin, vascular endothelial growth factor), and pH-weighted amine- chemical exchange saturation transfer (CEST) MRI to quantify tumor acidity at baseline and explore associations with drug response. Stage 1 enrolled 24 patients with early stoppage for ≤ 1 ORR. Of the 24 enrolled patients, median age was 62.1 (38.7–76.7) years, median KPS 80, MGMT promoter was methylated in 46% of tumors. PT2385 was well tolerated. Grade ≥ 3 drug-related adverse events were hypoxia (n = 2), hyponatremia (2), lymphopenia (1), anemia (1), and hyperglycemia (1). No objective radiographic responses were observed; median PFS was 1.8 months (95% CI 1.6–2.5) and OS was 7.7 months (95% CI 4.9–12.6). Drug exposure varied widely and did not differ by corticosteroid use (p = 0.12), antiepileptics (p = 0.09), or sex (p = 0.37). Patients with high systemic exposure had significantly longer PFS (6.7 vs 1.8 months, p = 0.009). Baseline acidity by pH-weighted CEST MRI correlated significantly with treatment duration (R2 = 0.49, p = 0.017). Non-enhancing infiltrative disease with high acidity gave rise to recurrence. PT2385 monotherapy had limited activity in first recurrent GBM. Drug exposure was variable. Signals of activity were observed in GBM patients with high systemic exposure and acidic lesions on CEST imaging. A second-generation HIF2α inhibitor is being studied.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s11060-023-04456-7

Cites

15 of 15 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 15 references

Research works printed but not linked: 34

  1. Stupp R, Mason W, van den Bent M et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. NEJM 352(10):987–996 · DOI · Paper page
  2. Malmström A, Grønberg BH, Marosi C et al (2012) Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma : the Nordic randomised, phase 3 trial. Lancet Oncol 13(9):916–926. https://doi.org/10.1016/S1470-2045(12)70265-6 · DOI · Paper page
  3. Wick W, Gorlia T, Bendszus M et al (2017) Lomustine and bevacizumab in progressive glioblastoma. N Engl J Med 377(20):1954–1963. https://doi.org/10.1056/NEJMOA1707358/SUPPL_FILE/NEJMOA1707358_DISCLOSURES.PDF · doi:10.1056/nejmoa1707358/suppl_file/nejmoa1707358_disclosures.pdf
  4. Weller M, Butowski N, Tran DD et al (2017) Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial. Lancet Oncol 18(10):1373–1385. https://doi.org/10.1016/S1470-2045(17)30517-X · DOI · Paper page
  5. Reardon DA, Kim TM, Frenel JS et al (2021) Treatment with pembrolizumab in programmed death ligand 1-positive recurrent glioblastoma: results from the multicohort phase 1 KEYNOTE-028 trial. Cancer 127(10):1620–1629. https://doi.org/10.1002/CNCR.33378 · DOI
  6. Reardon DA, Brandes AA, Omuro A et al (2020) Effect of nivolumab vs bevacizumab in patients with recurrent glioblastoma: the checkmate 143 phase 3 randomized clinical trial. JAMA Oncol 6(7):1003–1010. https://doi.org/10.1001/JAMAONCOL.2020.1024 · DOI · Paper page
  7. Axelson H, Fredlund E, Ovenberger M, Landberg G, Pahlman S (2005) Hypoxia-induced dedifferentiation of tumor cells—a mechanism behind heterogeneity and aggressiveness of solid tumors. Semi Cell Dev Biol 16:554–563 · DOI · Paper page
  8. Harris AL (2002) Hypoxia—a key regulatory factor in tumour growth. Nat Rev Cancer 2(1):38–47. https://doi.org/10.1038/nrc704 · DOI · Paper page
  9. Yu T, Tang B, Sun X (2017) Development of inhibitors targeting hypoxia-inducible factor 1 and 2 for cancer therapy. Yonsei Med J 58(3):489. https://doi.org/10.3349/ymj.2017.58.3.489 · DOI · Paper page
  10. Semenza GL, Agani F, Booth G et al (1997) Structural and functional analysis of hypoxia-inducible factor 1. Kidney Int 51(2):553–555 · DOI · Paper page
  11. Takeda N, O’Dea EL, Doedens A et al (2010) Differential activation and antagonistic function of HIF-{alpha} isoforms in macrophages are essential for NO homeostasis. Genes Dev 24(5):491–501. https://doi.org/10.1101/gad.1881410 · DOI · Paper page
  12. Gu YZ, Moran SM, Hogenesch JB, Wartman L, Bradfield CA (1998) Molecular characterization and chromosomal localization of a third alpha-class hypoxia inducible factor subunit, HIF3alpha. Gene Expr 7(3):205–213
  13. Dengler VL, Galbraith MD, Espinosa JM (2014) Transcriptional regulation by hypoxia inducible factors. Crit Rev Biochem Mol Biol 49(1):1–15. https://doi.org/10.3109/10409238.2013.838205 · DOI · Paper page
  14. Rey S, Schito L, Wouters BG, Eliasof S, Kerbel RS (2017) Targeting hypoxia-inducible factors for antiangiogenic cancer therapy. Trends Cancer 3(7):529–541. https://doi.org/10.1016/j.trecan.2017.05.002 · DOI
  15. Gatenby RA, Gillies RJ (2004) Why do cancers have high aerobic glycolysis? Nat Rev Cancer 4(11):891–899. https://doi.org/10.1038/NRC1478 · DOI · Paper page
  16. Jain RK, Di Tomaso E, Duda DG, Loeffler JS, Sorensen AG, Batchelor TT (2007) Angiogenesis in brain tumours. Nat Rev Neurosci 8(8):610–622. https://doi.org/10.1038/NRN2175 · DOI · Paper page
  17. Gatenby RA, Frieden BR (2004) Information dynamics in carcinogenesis and tumor growth. Mutat Res-Fundam Mol Mech Mutagen 568(2):259–273. https://doi.org/10.1016/j.mrfmmm.2004.04.018 · DOI
  18. Corbet C, Feron O (2017) Tumour acidosis: from the passenger to the driver’s seat. Nat Rev Cancer 17(10):577–593. https://doi.org/10.1038/NRC.2017.77 · DOI · Paper page
  19. Griffiths L, Stratford IJ (1998) The influence of elevated levels of platelet-derived endothelial cell growth factor/thymidine phosphorylase on tumourigenicity, tumour growth, and oxygenation. Int J Radiat Oncol Biol Phys 42(4):877–883. https://doi.org/10.1016/S0360-3016(98)00360-5 · doi:10.1016/s0360-3016(98)00360-5
  20. Shi Q, Le X, Wang B et al (2001) Regulation of vascular endothelial growth factor expression by acidosis in human cancer cells. Oncogene 20(28):3751–3756. https://doi.org/10.1038/SJ.ONC.1204500 · DOI · Paper page
  21. Hjelmeland AB, Wu Q, Heddleston JM et al (2011) Acidic stress promotes a glioma stem cell phenotype. Cell Death Differ 18(5):829–840. https://doi.org/10.1038/CDD.2010.150 · DOI · Paper page
  22. Wang YL, Yao J, Chakhoyan A et al (2019) Association between tumor acidity and hypervascularity in human gliomas using pH-weighted amine chemical exchange saturation transfer echo-planar imaging and dynamic susceptibility contrast perfusion MRI at 3T. AJNR Am J Neuroradiol 40(6):979–986. https://doi.org/10.3174/AJNR.A6063 · DOI
  23. Yao J, Chakhoyan A, Nathanson DA et al (2019) Metabolic characterization of human IDH mutant and wild type gliomas using simultaneous pH- and oxygen-sensitive molecular MRI. Neuro-oncology 21(9):1184–1196. https://doi.org/10.1093/NEUONC/NOZ078 · DOI
  24. Renfrow JJ, Soike MH, West JL et al (2020) Attenuating hypoxia driven malignant behavior in glioblastoma with a novel hypoxia-inducible factor 2 alpha inhibitor. Sci Rep. https://doi.org/10.1038/S41598-020-72290-2 · DOI · Paper page
  25. Wehn PM, Rizzi JP, Dixon DD et al (2018) Design and activity of specific Hypoxia-Inducible Factor-2α (HIF-2α) inhibitors for the treatment of clear cell renal cell carcinoma: discovery of clinical candidate (S)-3-((2,2-Difluoro-1-hydroxy-7-(methylsulfonyl)-2,3-dihydro-1 H-inden-4-yl)oxy)-5-fluorobenzonitrile (PT2385). J Med Chem 61(21):9691–9721. https://doi.org/10.1021/acs.jmedchem.8b01196 · DOI · Paper page
  26. Courtney K, Infante J, Lam E, et al (2016) A phase I dose escalation trial of PT2385, a first-in-class oral HIF-2a inhibitor, in patients with advanced clear cell renal cell carcinoma. In: ASCO Meeting Abstracts · DOI · Paper page
  27. Nusblat LM, Tanna S, Roth CM (2020) Gene silencing of HIF-2α disrupts glioblastoma stem cell phenotype. Cancer Drug Resist 3(2):199. https://doi.org/10.20517/CDR.2019.96 · DOI
  28. Ellingson BM, Wen PY, Cloughesy TF (2017) Modified criteria for radiographic response assessment in glioblastoma clinical trials. Neurotherapeutics 14(2):307–320. https://doi.org/10.1007/s13311-016-0507-6 · DOI · Paper page
  29. Ellingson BM, Bendszus M, Boxerman J et al (2015) Consensus recommendations for a standardized Brain Tumor Imaging Protocol in clinical trials. Neuro-oncology 17(9):1188–1198. https://doi.org/10.1093/NEUONC/NOV095 · DOI · Paper page
  30. Harris RJ, Cloughesy TF, Liau LM et al (2015) pH-weighted molecular imaging of gliomas using amine chemical exchange saturation transfer MRI. Neuro-oncology 17(11):1514–1524. https://doi.org/10.1093/NEUONC/NOV106 · doi:10.1093/neuonc/nov106
  31. Harris RJ, Yao J, Chakhoyan A et al (2018) Simultaneous pH-sensitive and oxygen-sensitive MRI of human gliomas at 3 T using multi-echo amine proton chemical exchange saturation transfer spin-and-gradient echo echo-planar imaging (CEST-SAGE-EPI). Magn Reson Med 80(5):1962–1978. https://doi.org/10.1002/MRM.27204 · DOI
  32. Yao J, Ruan D, Raymond C et al (2018) Improving B 0 correction for pH-weighted amine proton Chemical Exchange Saturation Transfer (CEST) imaging by use of k-means clustering and lorentzian estimation. Tomography 4(3):123–137. https://doi.org/10.18383/J.TOM.2018.00017 · doi:10.18383/j.tom.2018.00017
  33. Xie C, Gao X, Sun D et al (2018) Metabolic profiling of the novel hypoxia-inducible factor 2α inhibitor PT2385 in vivo and in vitro. Drug Metab Dispos 46(4):336–345. https://doi.org/10.1124/dmd.117.079723 · DOI
  34. Hirota T, Eguchi S, Ieiri I (2013) Impact of genetic polymorphisms in CYP2C9 and CYP2C19 on the pharmacokinetics of clinically used drugs. Drug Metab Pharmacokinet 28(1):28–37. https://doi.org/10.2133/dmpk.dmpk-12-rv-085 · DOI

Cited by

See all 36

Metadata

Authors
Strowd, R., Ellingson, B., Raymond, C., Yao, J., Wen, P. Y., Ahluwalia, M., Piotrowski, A., Desai, A., Clarke, J. L., Lieberman, F. S., Desideri, S., Nabors, L. B., Ye, X., & Grossman, S.
Venue
Journal of Neuro-Oncology
Published
2023-10
Volume
165
Issue
1
Pages
101-112
ISSN
  • 0167-594X (ISSN-L)
  • 1573-7373
OpenAlex
W4387845005
Cited by
36
References
15
FWCI
4.13
Type
journal article
Language
en
Open access
green
Licence
Funders
National Institutes of Health (UM1CA137443)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Activity of a first-in-class oral HIF2-alpha inhibitor, PT2385, in patients with first recurrence of glioblastoma. https://app.cochat.ai/papers/10.1007/s11060-023-04456-7
The paper
Strowd, R., Ellingson, B., Raymond, C., Yao, J., Wen, P. Y., Ahluwalia, M., Piotrowski, A., Desai, A., Clarke, J. L., Lieberman, F. S., Desideri, S., Nabors, L. B., Ye, X., & Grossman, S. (2023). Activity of a first-in-class oral HIF2-alpha inhibitor, PT2385, in patients with first recurrence of glioblastoma. Journal of Neuro-Oncology. https://doi.org/10.1007/s11060-023-04456-7

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.